Humanigen and avid bioservices enter into cgmp manufacturing agreement for covid-19 therapeutic candidate lenzilumab in support of potential eua filing

Burlingame, calif. & tustin, calif.--(business wire)--avid bioservices, inc. (nasdaq:cdmo) (nasdaq:cdmop) (“avid”) and humanigen, inc. (nasdaq:hgen) (“humanigen”) today announced that they have entered into a manufacturing services agreement to expand production capacity for lenzilumab™, humanigen's therapeutic candidate in development for covid-19. lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (gm-csf) monoclonal antibody designed to prevent and treat an immune h
CDMO Ratings Summary
CDMO Quant Ranking